Aniara is happy to announce the winner of the 2010 Aniara grant in the amount of $10,000 - Leonardo Brandao, MD.
Leonardo R. Brandao, MD
Haemostasis and Thrombosis Service
The Hospital for Sick Children
Clinical and Laboratory Diagnosis of Heparin-Induced Thrombocytopenia (HIT) in Children: a Prospective Pilot Study
1. To describe an inception cohort consisting of pediatric patients undergoing cardio-pulmonary bypass surgery (CPB) prospectively recruited upon their admission to The Hospital for Sick Children (Sickkids®). Subjects will be investigated prospectively for heparin-induced thrombocytopenia (HIT) by both heparin-PF4 (H-PF4) antibodies detected by enzyme immunoassays (ELISA) and by a confirmatory serotonin-release assay (SRA).
2. To compare the specificities and sensitivities of two ELISA screening assays in children tested for HIT regarding the detection of H-PF4 antibodies; the former laboratory method will be using 3 immunoglobulin (Ig) subclasses (IgA, IgM, and IgG); the latter will be testing only the IgG subclass.
3. To evaluate the potential use of clinical predictive tools previously develop for the investigation of HIT in adults in a pediatric population (i.e., the 4T score and the score developed by Lillo-Le et al for patients post-CPB)
4. To stratify the HIT assay results by patient type (i.e., use of the PELOD clinical severity score), pre-test risk assessment by two previously described clinical scoring system, and correlate these with their respective clinical-laboratory outcomes (incidence of thrombocytopenia, thrombosis, changes in anticoagulation therapy, and mortality).
5. The compare the clinical (thrombosis and mortality rates) and laboratory (thrombocytopenia) outcomes of pediatric patients undergoing CPB with the results of H-PF4 antibodies detected only by ELISA methods.
Full Text of Study - Clinical and Laboratory Diagnosis of Heparin-Induced Thrombocytopenia (HIT) in Children: a Prospective Pilot Study
2013 - Luigi Brunetti, PharmD, MPH, BCPS, CGP
2010 - Leonardo R. Brandao, MD
2009 - Dr. Mirta Schattner Ph.D.
2008 - Dr. Graciela Krikun, Ph.D.
2007 - Dr. Margaret Prechel, Ph.D.
2006 - Dr. A. Valance Washington, Ph.D
Dr. Dorothy Adcock
Medical Director/Laboratory Director Colorado Coagulation Consultants, Inc, dba Esoterix Coagulation Denver, Colorado
Dr. Kenneth A. Bauer
Professor of Medicine, Harvard Medical School. His hospital positions include Chief, Hematology Section, VA Boston Healthcare System, and Director, Thrombosis Clinical Research, Beth Israel Deaconess Medical Center.
Dr. Charles S. Eby
Associate Director of Educational Programs, Division of Laboratory Medicine at Washington University Saint Louis, Member of Barnes-Jewish Hospital Credentialing and Health Information Management Committees.
Dr. Andreas Hillarp
Position as hospital chemist at the Department of Clinical Chemistry, University Hospital, MalmÃ¶, Sweden.
Dr. Mervyn A. Sahud, M.D., A.B.I. M.-Hem.
Medical Director Coagulation Department Quest Diagnostics Nichols Institute
Dr. Sam Schulman
Associate professor in Internal Medicine at Karolinska Institute and since September 2004 also professor in medicine at McMaster University.
Agneta Siegbahn, MD, Ph.D.
Professor in Clinical Coagulation Science Department of Medical Sciences, Clinical Chemistry Akademiska Hospital, Uppsala, Sweden
Jogin R. Wu, Ph.D.
Associate Clinical Professor of Pathology, Duke University Medical Center. Associate Director, Clinical Coagulation Laboratory, Duke University Health System.